glp 1 bmi 27 requirements for A Balancing Act: GLP-1 Receptor Agonists Non-Diabetic Obesity – Clinical Correlations Medicare GLP-1 Drug Coverage More Pediatric Data Supporting GLP-1

490,491 The UK Prospective Diabetes Study indicated a modest reduction in neuropathy risk with improved glycemic control

62-65% of pregnant women use acetaminophen during pregnancy By 9 months of age: Up to 95% of children have been exposed to acetaminophen NEURODEVELOPMENTAL DISORDER PREVALENCE TIMELINE[] 1960s: Prevalence estimated at 1 in 10,000 1980s: Prevalence rises to 1 in 2,000 Late 1980s-1990s: Rates begin dramatic increase Late 1990s: Prevalence reaches 1 in 200 1996-2010: 269% increase in ASD prevalence (Atlanta surveillance data) 2021: Prevalence reaches 1 in 44 in the United States 1998-2018: 787% increase in recorded incidence in the UK THE TEMPORAL PATTERN The dramatic rise began in the late 1980s and accelerated through the 1990s and 2000sapproximately 25-30 years after acetaminophens introduction and widespread adoption in pregnancy, and coinciding with increased use for post-vaccination symptom management in infants

In exchange for the license, Ascendis will be eligible to receive total payments of up to $285 million in upfront, development, and regulatory milestone payments for the lead program

Improves roughness, acne marks, and uneven tone simultaneously

Nachnani, R., Raup-Konsavage, W